U.S. Systemic Inflammatory Response Syndrome Treatment Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 4.88 Bn

Forecast Year, 2035

USD 8.83 Bn

CAGR, 2026 - 2035

6.11%

Report Coverage

U.S.

What is the U.S. Systemic Inflammatory Response Syndrome Treatment Market Size in 2026?

The U.S. systemic inflammatory response syndrome treatment market size was calculated at USD 4.88 billion in 2025 and is predicted to increase from USD 5.28 billion in 2026 to approximately USD 8.83 billion by 2035, expanding at a CAGR of 6.11% from 2026 to 2035. The market is driven by rising SIRS cases, improved diagnostic technologies, and stronger critical care protocols.

Key Takeaways

• By indication (cause/trigger), the infectious causes segment held the largest market share in 2025.
• By indication (cause/trigger), the non-infectious causes segment is expected to expand with the highest CAGR during the forecast period.
• By mode of administration, the injectable segment held the largest share of the market in 2025.
• By mode of administration, the oral segment is expected to grow at a significant CAGR between 2026 and 2035.
• By end-user, the hospital and ambulatory surgical centers segment dominated the market in 2025.
• By end-user, the specialty clinics segment is expected to grow with the highest CAGR during the forecast period.
• By application, the autoimmune diseases segment held a significant share of the market in 2025.
• By application, the urinary tract infection (UTI) segment is expected to grow at a considerable rate in the coming years.

Market Overview

The U.S. systemic inflammatory response syndrome treatment market represents an important segment of the critical care and emergency medicine landscape, driven by the increasing incidence of severe infections, trauma, burns, and surgical complications. SIRS is characterized by an excessive inflammatory response to infectious or non-infectious triggers and can progress to sepsis, organ failure, and other life-threatening complications if not diagnosed and managed promptly.

Market growth is being supported by rising hospital admissions related to sepsis and critical illnesses, increasing demand for advanced intensive care treatments, and ongoing advancements in diagnostic and patient monitoring technologies. Greater awareness of early intervention strategies, expansion of critical care infrastructure, and continued research into anti-inflammatory and supportive therapies are further contributing to the market's development.

AI-Powered Advancements Transforming SIRS Treatment in the U.S.

The introduction of artificial intelligence has undoubtedly revolutionized the way that systemic inflammatory response syndrome is treated by enabling earlier diagnosis, improved risk stratification, and more personalized patient care. AI-powered monitoring systems, predictive analytics tools, and clinical decision-support platforms help healthcare providers identify patient deterioration more quickly and optimize treatment strategies in critical care settings. Growing adoption of digital health technologies and increasing investments in machine learning are further driving demand for AI-based solutions across hospitals, healthcare facilities, and research institutions. These advancements are enhancing clinical decision-making, improving patient outcomes, and fostering innovation in the SIRS treatment landscape.

Market Scope

Market Dynamics

Drivers

Rising Incidence of Severe Infections and Sepsis

The increasing incidence of severe infections such as sepsis, along with trauma-related injuries and surgical complications, is a major factor driving demand for SIRS treatments. Rising hospital admissions for critically ill patients have heightened the need for rapid diagnosis, continuous monitoring, and effective therapeutic interventions to prevent disease progression and improve outcomes. Additionally, the growing elderly population and rising prevalence of chronic diseases are increasing the demand for advanced treatment options and critical care services for patients with SIRS.

Restraint

Challenges in Early and Accurate Diagnosis

The difficulty in distinguishing between SIRS and other conditions relating to inflammation or infection is one of the major challenges for the market. Common symptoms such as fever, elevated heart rate, and rapid breathing are nonspecific, making early and accurate diagnosis difficult. The lack of a universally accepted biomarker further complicates patient identification and clinical decision-making, potentially delaying treatment initiation and limiting the adoption of SIRS-specific therapies.

Opportunity

Development of Targeted Immunomodulatory Therapies

The growing focus on precision medicine presents significant opportunities in the systemic inflammatory response syndrome treatment market. Researchers and pharmaceutical companies are increasingly developing targeted immunomodulatory therapies aimed at controlling excessive inflammatory responses while preserving normal immune function. Rising investment in critical care research and innovative therapeutic development is expected to accelerate the introduction of advanced treatment options, creating new growth avenues and expanding the overall market potential in the coming years.

Why is the Demand for SIRS Treatment Growing in the U.S.?

In the U.S., the demand for systemic inflammatory response syndrome (SIRS) treatment is growing due to the country's advanced healthcare system and the widespread availability of critical care services. In addition, an overall increase in the number of people suffering from serious infections, trauma, surgery, burns, and chronic diseases is also contributing to an increased demand for effective SIRS treatment within the country's hospitals and emergency departments.

A recent nationwide study involving 103,701 emergency department patient encounters examined 372 million total ED encounters by adults and determined that about 17.8% of ED patients had evidence of SIRS; therefore, there are approximately 16.6 million total cases of SIRS in adult ED patients each year. This large number illustrates that SIRS represents a significant clinical burden on the U.S. healthcare system and highlights the need for the rapid identification of SIRS patients; supportive therapies; anti-inflammatory therapies; and intensive care treatment of patients with SIRS in the U.S.

Segment Insights

Indication Insights(Cause/Trigger)

The infectious causes segment led the U.S. systemic inflammatory response syndrome treatment market in 2025, as these are the most common triggers for developing systemic inflammation. As such, the treatment of infection-based SIRS is expected to continue to be a major demand source, particularly due to the high rates of sepsis-related complications, ongoing rates/levels of hospitalization for acute infection, and ongoing needs for rapid antimicrobial support therapy.

The non-infectious causes segment is expected to grow at the fastest CAGR in the coming years due to rising levels of trauma, pancreatitis, surgical complications, and autoimmune disease. Greater awareness of non-infectious inflammatory responses, advances in diagnostic techniques, and the introduction of new, targeted therapies are expected to increase the use of earlier intervention, resulting in the expansion of total treatment utilization within this segment.

Mode of Administration Insights

The injectable segment held the largest share of the U.S. systemic inflammatory response syndrome treatment market in 2025. This is because many patients with SIRS require immediate treatment due to being in either an emergency department or a critical care setting. The use of intravenous injection allows for rapid administration of the medication into the bloodstream, along with precise dosing and faster onset of effect.

The oral segment is expected to expand at the fastest rate during the forecast period because patients have more convenient ways to take medication and require less time in a hospital to manage their condition. Additionally, there is a growing availability of oral anti-inflammatory and other supportive medications for patients with SIRS. The combination makes it appealing to healthcare providers and patients as a cost-effective form of treatment.

Application Insights

The autoimmune disease segment held a significant share in the U.S. systemic inflammatory response syndrome treatment market in 2025 and is expected to continue its growth trajectory. This is mainly due to the high prevalence of chronic autoimmune conditions that frequently trigger systemic inflammatory responses requiring intensive management. Diseases such as rheumatoid arthritis, lupus, and inflammatory bowel disease often involve persistent immune system activation, increasing the risk of SIRS-like complications and driving demand for targeted anti-inflammatory and immunomodulatory therapies.

The UTI segment is expected to grow at a considerable rate over the projection period. This is due to the high prevalence of urinary tract infections, particularly in elderly and hospitalized patients, which can rapidly progress to severe systemic infections and trigger SIRS. The increasing incidence of catheter-associated UTIs in critical care settings further contributes to this risk, driving demand for early diagnosis and intensive treatment.

End User Insights

The hospital and ambulatory surgical centers segment dominated the U.S. systemic inflammatory response syndrome treatment market in 2025 because these facilities provide comprehensive emergency, surgical, and intensive care services. Patients with SIRS typically require continuous monitoring, advanced diagnostic tests, and multidisciplinary treatment, making hospitals and ASCs the best and most appropriate settings for the management of SIRS, as well as providing critical care interventions when necessary.

The specialty clinic segment is expected to grow at the fastest CAGR in the upcoming period due to the increasing need for specialized management and follow-up care for patients with Systemic Inflammatory Response Syndrome (SIRS). These clinics offer focused expertise and individualized treatment approaches, allowing for more tailored and effective disease management compared to generalized care settings.

U.S. Systemic Inflammatory Response Syndrome Treatment Market Value Chain Analysis

• Raw Material Sourcing

Manufacturers acquire the raw materials necessary to produce high-quality solar thermal collectors, which will be able to provide heating in their respective markets. These materials include copper, aluminum, tempered glass, insulation, and absorber coatings.

Key Players: Saint-Gobain, ArcelorMittal, Borosil Renewables, 3M, and Alcoa.

• Manufacturing

Manufacturers of flat plate and evacuated tube collectors are utilizing advanced absorber technologies, automated production processes, and thermal optimization techniques to enhance energy conversion efficiency.

Key Players: Viessmann, Greenonetec, Himin Solar, Rheem Manufacturing, and Bosch Thermotechnology.

• System Integration and Distribution

Distributors and system integrators assemble the collectors with the storage tanks, controllers, pumps, and piping required for a complete system while providing for product delivery, installation support, and operational performance.

Key Players: Vaillant Group, Wagner Solar, Racold, A.O. Smith, and Kingspan Group.

• End Use Application

Installers and service providers are deploying solar thermal systems to the residential, commercial, and industrial markets for water heating, space heating, and industrial process heating.

Key Players: Emmvee, SunEarth, Solahart, V-Guard Industries, and Chromagen.

Competitive Landscape

The U.S. systemic inflammatory response syndrome treatment market is moderately consolidated, with large pharmaceutical and critical care companies competing alongside smaller biotechnology firms. Major players such as Merck & Co., Johnson & Johnson, and AbbVie maintain strong positions due to their broad product portfolios, advanced therapeutic capabilities, and extensive distribution networks across the U.S. healthcare system, while emerging biotech companies are gaining traction through targeted anti-inflammatory therapies and biomarker-driven treatment approaches.

Competition in the market is primarily driven by continuous innovation in drug development, increasing strategic partnerships, mergers and acquisitions, and rising investments in clinical research aimed at improving patient outcomes. However, high R&D costs, strict regulatory requirements, and strong intellectual property protections create significant barriers to entry, making sustained innovation and differentiation essential for long-term competitiveness.

U.S. Systemic Inflammatory Response Syndrome Treatment Market Companies

• GlaxoSmithKline
• AstraZeneca
• CytoSorbents Corporation
• Cardinal Health
• Asahi Kasei
• ConvaTec
• CHIESI Farmaceutici

Recent Development

• In April 2026, AstraZeneca announced that the U.S. FDA approved Saphnelo (anifrolumab) for subcutaneous self-administration through the once-weekly Saphnelo Pen autoinjector, providing adults with systemic lupus erythematosus (SLE) a more convenient treatment option alongside standard therapy.

Segments Covered in the Report

By Indication (cause/trigger)

• Infectious causes
• Non-infectious causes
• UTI

By Mode of administration

• Injectable
• Oral

By End-User

• Hospital and ambulatory surgical centers
• Speciality Clinics

By Product Type

• Urinary Tract Infection (UTI)
• Autoimmune Diseases
• Meningitis
• Pneumonia
• Others